Who
James Samuel Shannon
Director
Company insider
Files Form 4 as: Director, Xilio Therapeutics; Director, MannKind; Director, Horizon Therapeutics Public Ltd Co; Director, Endocyte.
In numbers
- Trades disclosed
- 91
- Buys
- 3
- Sells
- 3
- Bought
- $136K
- Sold
- $1.3M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 24 Feb 2010
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,556 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,556 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K5,000 at $8.79 | filing |
| 26 Mar 2026filed 30 Mar 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Bought | $44K5,000 at $8.79 | filing |
| 1 Mar 2026filed 3 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $39K12,000 at $3.27 | filing |
| 1 Mar 2026filed 3 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $39K12,000 at $3.27 | filing |
| 17 Jun 2025filed 18 Jun 2025 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Bought | $17K25,000 at $0.69 | filing |
| 16 Jun 2025filed 18 Jun 2025 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Bought | $31K45,000 at $0.69 | filing |
| 11 Jun 2025filed 12 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —52,854 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,047 at $0.00 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —8,150 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —32,161 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Cooption or derivative | SEC FORM 4 Code D | —4,016 | filing |
| 6 Oct 2023filed 6 Oct 2023 | Horizon Therapeutics Public Ltd Co | SEC FORM 4 Code D | $3.9M33,156 at $116.50 | filing |
News
No headline names them, or the companies they trade most, lately.